Recombinant Human FXN Protein，His

The study of FXN (Frataxin) recombinant protein has gained significant attention due to its critical role in mitochondrial function and iron-sulfur cluster biosynthesis. Frataxin is a small mitochondrial protein encoded by the FXN gene, and its deficiency is associated with Friedreich's ataxia, a debilitating neurodegenerative disorder that leads to progressive loss of motor coordination, sensory loss, and diabetes. Patients with Friedreich's ataxia suffer from impaired mitochondrial energy production and increased oxidative stress resulting from iron accumulation. In recent years, researchers have focused on the potential of FXN recombinant protein as a therapeutic strategy to restore function and alleviate symptoms in affected individuals. Advances in protein expression systems have enabled the production of high-purity recombinant FXN, facilitating studies that decipher its biochemical properties, interaction with other mitochondrial proteins, and overall role in cellular metabolism. Furthermore, these studies have led to explorations of gene therapy and small molecule drugs aimed at increasing FXN levels in patients. Understanding the mechanistic pathways involving FXN has the potential not only to advance treatments for Friedreich's ataxia but also to provide insights into other mitochondrial disorders, making FXN recombinant protein a focal point of contemporary biomedical research.